Synairgen breathes easier with $225M from Astrazeneca for its asthma drug
After two years of discussions, Synairgen plc has landed Astrazeneca plc as partner for its asthma treatment SNG001 in a $225 million deal. Astrazeneca will pay $7.25 million up front and now takes over development of SNG001, an inhaled formulation of interferon beta.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter